Space for Calaspargase? A New Asparaginase for Acute Lymphoblastic Leukemia
- PMID: 31641006
- DOI: 10.1158/1078-0432.CCR-19-2975
Space for Calaspargase? A New Asparaginase for Acute Lymphoblastic Leukemia
Abstract
In December 2018, the FDA approved calaspargase pegol-mknl (Asperlas, Servier Pharmaceuticals) for acute lymphoblastic leukemia (ALL) in children and young adults up to age 21. Asparaginase is a critical component in the treatment of ALL, but the niche for calaspargase within current treatment protocols is unclear.See related article by Li et al., p. 328.
©2019 American Association for Cancer Research.
Comment in
-
FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults.Clin Cancer Res. 2020 Jan 15;26(2):328-331. doi: 10.1158/1078-0432.CCR-19-1255. Epub 2019 Aug 23. Clin Cancer Res. 2020. PMID: 31444252
Comment on
-
FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults.Clin Cancer Res. 2020 Jan 15;26(2):328-331. doi: 10.1158/1078-0432.CCR-19-1255. Epub 2019 Aug 23. Clin Cancer Res. 2020. PMID: 31444252
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources